STAAR Surgical Co. - 10-Q Summary (Q1 1995)
Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for STAAR Surgical Company for the three-month period ended March 31, 1995. The company manufactures and sells intraocular lenses (IOLs) for cataract surgery. As of May 11, 1995, the company had 12,801,064 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q1 1995 | Q1 1994 |
|---|---|---|
| Total Revenues | $7,307,599 | $5,771,998 |
| Net Income | $1,645,969 | $1,131,683 |
| Gross Margin | 76.0% | 77.7% |
| Operating Income | $1,588,012 | $909,657 |
| Cash and Equivalents | $3,399,848 | $813,435 |
| Net Working Capital | $14.8 million | N/A |
| Current Ratio | 3.6:1 | N/A |
| Total Debt (Current + Long Term) | $2.9 million | N/A |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 26.6% to $7.3 million, driven by expanding international sales in Europe, South Africa, and Australia, alongside continued U.S. market acceptance.
- Profitability: Net income rose 45.4% to $1.6 million. Operating income increased significantly to $1.6 million from $0.9 million.
- Expense Management: General & Administrative (G&A) expenses decreased as a percentage of revenue (14.1% vs 22.8%) due to cost controls and reduced management personnel. Conversely, Marketing & Selling expenses increased to 30.1% of revenue to support international expansion.
- Cash Flow: Net cash provided by operating activities turned positive at $1.7 million, compared to a use of $0.1 million in the prior year. This was offset by significant investing outflows ($1.3 million) for property and patents, and financing outflows ($0.2 million) primarily due to stock repurchases.
- Royalty Income: Royalty income dropped to zero in Q1 1995 from $239,000 in Q1 1994.
Outlook, Risks, and Unusual Items
- Regulatory Approval: On April 3, 1995, the FDA approved the company's Ultraviolet (UV) absorbing material for use in IOLs in the United States.
- Stock Repurchase: The company utilized approximately $1.0 million of working capital to repurchase roughly 100,000 shares of common stock. Management intends to continue buying back up to 1,000,000 shares, options, or warrants as feasible.
- Future Guidance: Management expects to remain profitable and believes future cash flow needs will be met by operations. R&D spending is expected to remain around 10% of revenues.
- Pricing Pressure: Cost of Sales increased to 24.0% of revenue (from 22.3%) primarily due to reduced pricing in the domestic market.
- Liquidity: The company maintains a strong liquidity position with a current ratio of 3.6:1 and net equity of $23.3 million.
Investor Verification Checklist
- Verify the sustainability of the 26.6% revenue growth rate given the drop in royalty income and domestic pricing pressures.
- Confirm the impact of the new FDA UV approval on future product mix and margins.
- Monitor the pace of the stock repurchase program and its effect on cash reserves.
- Review the composition of the $1.3 million investing outflow to ensure alignment with long-term growth strategy.
- Assess the risk of further margin compression if domestic pricing trends continue.